Last Updated: September 24, 2026

Details for Patent: 12,133,837


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 12,133,837 protect, and when does it expire?

Patent 12,133,837 protects ADRENALIN and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 12,133,837
Title:Epinephrine compositions and containers
Abstract:The inventive subject matter provides ready-to-administer, preferably anti-oxidant free, epinephrine compositions with improved stability, and methods for preparing the same. Contemplated compositions can be packaged using blow-fill-seal technology or packaged into flexible IV bags and maintain degradation of the epinephrine at a level of less than 5 wt % when stored over at least one months at between 2-40° C.
Inventor(s):Prem Sagar Akasapu, Kumaresh Soppimath, Reema Ajitkumar Puri, Iouri V. Ilitchev, Milan Patel, Pooja H. Tendulkar
Assignee: Nevakar Injectables Inc
Application Number:US17/526,786
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 12,133,837
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 12,133,837

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ph Health ADRENALIN epinephrine SOLUTION;INTRAVENOUS 215875-001 Apr 21, 2023 RX Yes Yes 12,133,837 ⤷  Start Trial Y ⤷  Start Trial
Ph Health ADRENALIN epinephrine SOLUTION;INTRAVENOUS 215875-002 Apr 21, 2023 RX Yes Yes 12,133,837 ⤷  Start Trial Y ⤷  Start Trial
Ph Health ADRENALIN epinephrine SOLUTION;INTRAVENOUS 215875-003 Apr 21, 2023 RX Yes Yes 12,133,837 ⤷  Start Trial Y ⤷  Start Trial
Ph Health ADRENALIN epinephrine SOLUTION;INTRAVENOUS 215875-004 Apr 21, 2023 RX Yes Yes 12,133,837 ⤷  Start Trial Y ⤷  Start Trial
Ph Health ADRENALIN epinephrine SOLUTION;INTRAVENOUS 215875-005 Apr 21, 2023 RX Yes Yes 12,133,837 ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 12,133,837

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 3093725 ⤷  Start Trial
World Intellectual Property Organization (WIPO) 2019183416 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.